Research ArticleClinical (Oncology: Lung)
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg and Grace Kong
Journal of Nuclear Medicine February 2022, 63 (2) 218-225; DOI: https://doi.org/10.2967/jnumed.120.260760
Lamiaa Zidan
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Amir Iravani
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;
3Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, Missouri;
Kira Oleinikov
4Neuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
Simona Ben-Haim
5Department of Nuclear Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
6Institute of Nuclear Medicine, University College London and UCL Hospitals NHS Trust, London United Kingdom;
David J. Gross
4Neuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
Amichay Meirovitz
7Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and
Ophra Maimon
7Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and
Tim Akhurst
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;
Michael Michael
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;
8Division of Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Rodney J. Hicks
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;
Simona Grozinsky-Glasberg
4Neuroendocrine Tumor Unit, ENETS Center of Excellence, Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
Grace Kong
1Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 2
February 1, 2022
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg, Grace Kong
Journal of Nuclear Medicine Feb 2022, 63 (2) 218-225; DOI: 10.2967/jnumed.120.260760
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg, Grace Kong
Journal of Nuclear Medicine Feb 2022, 63 (2) 218-225; DOI: 10.2967/jnumed.120.260760
Jump to section
Related Articles
Cited By...
- No citing articles found.